Xceleron and Organon sign microdose study agreement
The three selected drug candidates are all compounds that have emerged from Organon's gynaecological research and development activities. The purpose of the human microdose study is to quickly assess all important pharmacokinetic properties of the compounds whilst confirming the scalability of the microdose to pharmacological dose for these compounds. Xceleron will use its ultra-sensitive Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!